Trust Size
$53M
Peak Price
$105.40
Current Price
$0.90
Return
-91.0%
Price Journey
What Happened
Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit technology platform.
Senti Biosciences went public through a SPAC merger and trades under SNTI. The company engineers synthetic biology 'gene circuits' that can be programmed into cell therapies to make them smarter and more effective against cancer. The stock has declined significantly and the company faces the typical challenges of a pre-revenue clinical-stage biotech, with a reverse stock split executed to maintain listing compliance.
Timeline
2021-05-21
S-1 Registration Filed
2022-05-13
Merger Proxy Filed (DEFM14A)
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1854270
Total SEC Filings
309
State of Incorporation
DE
Last Filing Date
2026-03-19
Business Location
Redwood City, CA
Trust/Asset Size
$53M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Senti Biosciences